Open Access Peer-reviewed Review

Skin toxicities related to targeted therapy and immunotherapy for non-small cell lung cancer

Article Sidebar

Download PDF
Submitted   Nov 5, 2024
Published   Mar 20, 2025
Issue    Vol 6 (2024)
DOI   10.25082/CCR.2024.01.006

Views

85

Downloads

38

Citations

PlumX Metrics

Main Article Content

Jia Yan
Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China
Min Zhang corresponding author
Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China

Abstract

 Non-small cell lung cancer (NSCLC) is the most common cancer, causing death and disability. Targeted therapy and immunotherapy have had an increasing role in the management of patients with advanced NSCLC. These treatments can produce an excellent curative effect, but the side effects should not be ignored. Skin toxicities such as papulopustular eruption, severe desquamation, and paronychia have a high incidence, seriously affecting patients’ quality of life and even interrupting treatment. Early recognition and adequate management are critical to prevent exacerbation of the lesions. This review describes the common skin toxicities related to targeted therapy and immunotherapy for NSCLC, summarizes the updated research progress of the mechanism, and proposes appropriate treatment and counseling for optimized management.

Keywords
non-small cell lung cancer, immunotherapy, targeted therapy, skin toxicities

Article Details

How to Cite
Yan, J., & Zhang, M. (2025). Skin toxicities related to targeted therapy and immunotherapy for non-small cell lung cancer. Current Cancer Reports, 6(1), 248-253. https://doi.org/10.25082/CCR.2024.01.006
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

References

  1. Satoh TK, Mellett M, Meier-Schiesser B, et al. IL-36$gamma$ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. Journal of Clinical Investigation. 2020, 130(3): 1417-1430. https://doi.org/10.1172/jci128678
  2. Chularojanamontri L, Tuchinda P, Likitwattananurak C, et al. Cutaneous toxicities of epidermal growth factor receptor inhibitors: A prospective study in 60 Asian patients. Asian Pacific Journal of Allergy and Immunology. 2019, 37(1): 12-18.
  3. Gisondi P, Geat D, Mattiucci A, et al. Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer. Dermatology. 2021, 237(6): 929-933. https://doi.org/10.1159/000513233
  4. Peng Y, Li Q, Zhang J, et al. Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors. BioScience Trends. 2018, 12(6): 537-552. https://doi.org/10.5582/bst.2018.01246
  5. Vos T, Flaxman A D, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. The lancet, 2012, 380(9859): 2163-2196.
  6. Li B, Chan HL, Chen P. Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry. 2019, 26(17): 3009-3025. https://doi.org/10.2174/0929867324666170804143706
  7. Wei SC, Levine JH, Cogdill AP, et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell. 2017, 170(6): 1120-1133.e17. https://doi.org/10.1016/j.cell.2017.07.024
  8. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2019, 381(21): 2020-2031. https://doi.org/10.1056/nejmoa1910231
  9. Carbone DP, Reck M, Paz-Ares L, et al. First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2017, 376(25): 2415-2426. https://doi.org/10.1056/nejmoa1613493
  10. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet, 2019, 393(10183): 1819-1830.
  11. Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer. JAMA. 2019, 322(8): 764. https://doi.org/10.1001/jama.2019.11058
  12. Koyama S, Akbay EA, Li YY, et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research. 2016, 76(5): 999-1008. https://doi.org/10.1158/0008-5472.can-15-1439
  13. Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2020, 383(18): 1711-1723. https://doi.org/10.1056/nejmoa2027071
  14. Zhong WZ, Chen KN, Chen C, et al. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non–Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. Journal of Clinical Oncology. 2019, 37(25): 2235-2245. https://doi.org/10.1200/jco.19.00075
  15. Lynch TJ, Kim ES, Eaby B, et al. Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management. The Oncologist. 2007, 12(5): 610-621. https://doi.org/10.1634/theoncologist.12-5-610
  16. Roé E, García Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients. Journal of the American Academy of Dermatology. 2006, 55(3): 429-437. https://doi.org/10.1016/j.jaad.2006.04.062
  17. Schaake EE, Kappers I, Codrington HE, et al. Tumor Response and Toxicity of Neoadjuvant Erlotinib in Patients With Early-Stage Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2012, 30(22): 2731-2738. https://doi.org/10.1200/jco.2011.39.4882
  18. Chandra F, Sandiono D, Sugiri U, et al. Cutaneous Side Effects and Transepidermal Water Loss To Gefitinib: A Study of 11 Patients. Dermatology and Therapy. 2016, 7(1): 133-141. https://doi.org/10.1007/s13555-016-0163-0
  19. Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. British Journal of Dermatology. 2001, 144(6): 1169-1176. https://doi.org/10.1046/j.1365-2133.2001.04226.x
  20. Boone SL, Rademaker A, Liu D, et al. Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results. Oncology. 2007, 72(3-4): 152-159. https://doi.org/10.1159/000112795
  21. De Luca R, Lo Coco G, Addeo R, et al. Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodies (Our Experience With Cetuximab). World Journal of Oncology. 2021, 12(4): 104-110. https://doi.org/10.14740/wjon1381
  22. Gangemi S, Franchina T, Minciullo PL, et al. IL‐33/IL‐31 axis: A new pathological mechanisms for EGFR tyrosine kinase inhibitors‐associated skin toxicity. Journal of Cellular Biochemistry. 2013, 114(12): 2673-2676. https://doi.org/10.1002/jcb.24614
  23. Herbst RS, LoRusso PM, Purdom M, et al. Dermatologic Side Effects Associated with Gefitinib Therapy: Clinical Experience and Management. Clinical Lung Cancer. 2003, 4(6): 366-369. https://doi.org/10.3816/clc.2003.n.016
  24. Molinari E, De Quatrebarbes J, André T, et al. Cetuximab-Induced Acne. Dermatology. 2005, 211(4): 330-333. https://doi.org/10.1159/000088502
  25. Blumental G. Paronychia and pyogenic granuloma-like lesions with isotretinoin. Journal of the American Academy of Dermatology. 1984, 10(4): 677-678. https://doi.org/10.1016/s0190-9622(84)80289-3
  26. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Annals of Oncology. 2005, 16(9): 1425-1433. https://doi.org/10.1093/annonc/mdi279
  27. Boucher KW, Davidson K, Mirakhur B, et al. Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody. Journal of the American Academy of Dermatology. 2002, 47(4): 632-633. https://doi.org/10.1067/mjd.2002.124621
  28. Dainichi T, Tanaka M, Tsuruta N, et al. Development of Multiple Paronychia and Periungual Granulation in Patients Treated with Gefitinib, an Inhibitor of Epidermal Growth Factor Receptor. Dermatology. 2003, 207(3): 324-325. https://doi.org/10.1159/000073100
  29. Shah NT, Kris MG, Pao W, et al. Practical Management of Patients With Non–Small-Cell Lung Cancer Treated With Gefitinib. Journal of Clinical Oncology. 2005, 23(1): 165-174. https://doi.org/10.1200/jco.2005.04.057